Research

Contribute to the future of psilocybin therapy research 

 

Health research is important because it tells us about what works best. Health care professionals and health system decision-makers use health research for many reasons, including but not limited to: 

  • Making advances and improvements in tests and diagnoses, treatments, medicines, and devices. 
  • Informing the way health care services are delivered. 

Health research is also important to patients and their families; helping them make informed decisions about their care plan.

A team of clinicians and end-of-life specialists; alongside partners from Victoria Hospice, TheraPsil, and the psychedelic medicine assisted therapy community, are interested in generating evidence that explores the use of psilocybin in the compassionate treatment of end-of-life emotional distress

We want to listen and learn from patients to ensure future research activities reflect patient priorities and interests. 

If you have received or are considering receiving psilocybin-assisted therapy for end-of-life distress, we want to hear from you!

What do you think are important topics related to Psilocybin-Assisted Therapy and end-of-life emotional distress that researchers should generate evidence on next? This is your opportunity to share your story and chart the future of psilocybin-assisted therapy!

*Prior knowledge about health research is not required.

The Current Research

“Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life.

Ross et al. 2016

“Psilocybin produced large and significant decreases in clinician-rated and self-rated measures of depression, anxiety or mood disturbance, and increases in measures of quality of life, life meaning, death acceptance, and optimism. These effects were sustained at 6 months.”

Griffiths et al. 2016

We have developed a comprehensive reading list of original scientific research papers from the past decade relating to psilocybin-assisted psychotherapy in the treatment of end-of-life distress.

The items in this bibliography collectively document that more than 2000 doses of psilocybin have been safely administered since the early ‘90s.

Collectively, they indicate that psilocybin-assisted psychotherapy is an effective and low-risk treatment for end-of-life distress when conducted according to research-established protocols by suitably trained therapists.

Comments are closed.

Want to sign up for our Newsletter to stay in the loop?

Subscribe